Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Charming (MCTA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Charming Medical common stock between October 10, 2025, and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- What ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Charming (MCTA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Charming Medical common stock between October 10, 2025, and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- What’ ...

SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in  NASDAQ: MCTA shares over alleged securities laws violations by Charming Medical Limited. Investors who purchased shares of Charming Medical Limited (NASDAQ: MCTA) have certain options and there are short and strict deadlines running. Deadline: February 17, 2026. NASDAQ: MCTA investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. O ...

SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or ...

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or g ...

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Price Movement - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [6]. Group 1: Allegations and Legal Actions - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share without any fundamental news justifying such a spike [6]. Group 2: Trading Suspension and Investor Rights - Trading of Charming's stock was halted by the SEC on November 12, 2025, due to the company's failure to provide required information to lift the suspension [6]. - Investors who purchased Charming shares during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights and options [4][6]. Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation and has a nationwide practice [5].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant price inflation of its shares during a specific period [6]. Group 1: Allegations - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that inflated the stock price [6]. Group 2: Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [6]. Group 3: Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [6]. Group 4: Legal Process - Investors who purchased Charming shares between October 10, 2025, and November 12, 2025, have until February 17, 2026, to apply to be appointed as lead plaintiff in the lawsuit [6].

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Charming Medical Ltd. (NASDAQ: MCTA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Charming securities between October 10, 2025 and November 12, 2026, b ...

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations that Charming and certain officers and/or directors engaged in securities fraud [2]. - Investors have until February 17, 2026, to request to be appointed as Lead Plaintiff if they purchased Charming securities during the Class Period [2]. Group 2: Stock Performance and SEC Action - On November 11, 2025, Charming's stock closed at $29.36, with an intraday high of $31.70, and had approximately 17.18 million shares outstanding, resulting in a market capitalization of around $504 million [4]. - Following this, the SEC halted trading of Charming securities from November 12 through 25, 2025, due to allegations of price manipulation through social media, which was part of a "pump-and-dump" scheme [4].